Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European center
Avtorji:Ivanović, Marija (Avtor)
Knez, Lea (Avtor)
Herzog, Ana (Avtor)
Kovačević, Mile (Avtor)
Čufer, Tanja (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede:non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Leto izida:2021
Založnik:AlphaMed Press
Izvor:ZDA
UDK:616-006
ISSN pri članku:1549-490X
COBISS_ID:76794115 Povezava se odpre v novem oknu
DOI:10.1002/onco.13909 Povezava se odpre v novem oknu
Opombe:Nasl. z nasl. zaslona; Soavtorji: Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer; Opis vira z dne 17. 9. 2021;
Število ogledov:139
Število prenosov:38
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://theoncologist.onlinelibrary.wiley.com/doi/epdf/10.1002/onco.13909
 
Nadgradivo:Oncologist
AlphaMed Press
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© 2021 Alpha Med Press
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Nazaj